Adalimumab, an anti-tumor necrosis factor (TNF) mAb, has been approved for the treatment of noninfectious uveitis, providing an alternative for patients who are unresponsive to conventional immunosuppressive therapies [13,14,15]. The gene discussed is TNF; the disease is uveitis.